<DOC>
	<DOCNO>NCT00777764</DOCNO>
	<brief_summary>This study enrol 30 healthy volunteer 30 patient atopic asthma , total 60 subject . The study examine tolerability omalizumab omalizumab excipients two successive cohort subject , healthy volunteer patient allergic asthma without prior exposure omalizumab , accord skin test protocol , consist prick skin test and/or intradermal test .</brief_summary>
	<brief_title>The Safety Utility Skin Testing With XOLAIRÂ® ( Omalizumab ) Placebo Omalizumab ( Formulation Excipients )</brief_title>
	<detailed_description />
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<criteria>( Applicable healthy subject ) Healthy subject take regular prescription medication , without history allergy , consider healthy physician ( Applicable asthma patient ) Patients atopic asthma diagnose physician asthma history positive skin test ( ) Physical examination finding within normal limit Body mass index ( BMI ) 18 30 , inclusive Pregnancy lactation Current previous treatment biologic agent ( e.g. , monoclonal antibody ) Concurrent disease condition would interfere , treatment might interfere conduct study , would , opinion investigator , pose unacceptable risk individual study History symptom significant psychiatric disease , include limited , depression , schizophrenia , etc . History drug abuse Participation investigational drug device trial within last 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Xolair</keyword>
	<keyword>Asthma</keyword>
	<keyword>Skin Tests</keyword>
</DOC>